Clinical Trial Update: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial of DS107 for adults with moderate to severe atopic dermatitis was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DS107

Snippet

Sponsor: DS Biopharma | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2022-05-06